focus -WSS

focus

author：leisure time 2025-09-30 17:44:11 - browse：5248

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Eli Lilly’s Zepbound improved liver scarring in mid

explore

WSS

New weight loss drugs work. But how can they best be used?

AdventHealth escalates lawsuit against insurance vendor Multiplan

Sutter Health’s antitrust win overturned by appeals court

Feng Zhang, Grail founder join forces on new gene editing startup

Eli Lilly’s Zepbound improved liver scarring in mid

U.K. sequencing study surfaces new findings about tumor DNA

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Activists slam private health insurers over coverage restrictions

Congress needs to close a vaccine

Hepatitis C has a cure — but many Americans still lack access to it

Federal weight loss drug coverage is 30 years out of date

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

FDA approves Moderna’s RSV vaccine, its second licensed product

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

leisure time

Data don't support strong claims for Covid

ASCO Takeaways: Winners, snoozers, and the art of cancer care

STAT wants to know your pick for a great summer read or listen

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

An outdated Medicare rule harms dementia patients with anxiety

GSK Flovent asthma inhalers replaced by authorized generics

focus

entertainment

explore

leisure time